ATE227268T1 - Alpha v beta 3 antagonisten - Google Patents
Alpha v beta 3 antagonistenInfo
- Publication number
- ATE227268T1 ATE227268T1 AT97920270T AT97920270T ATE227268T1 AT E227268 T1 ATE227268 T1 AT E227268T1 AT 97920270 T AT97920270 T AT 97920270T AT 97920270 T AT97920270 T AT 97920270T AT E227268 T1 ATE227268 T1 AT E227268T1
- Authority
- AT
- Austria
- Prior art keywords
- beta
- alpha
- antagonists
- compounds
- inhibiting
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000002464 receptor antagonist Substances 0.000 abstract 2
- 229940044551 receptor antagonist Drugs 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical class C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1517796P | 1996-04-10 | 1996-04-10 | |
| GBGB9610996.2A GB9610996D0 (en) | 1996-05-24 | 1996-05-24 | µv›3 Antagonists |
| PCT/US1997/005890 WO1997037655A1 (en) | 1996-04-10 | 1997-04-08 | αvβ3 ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE227268T1 true ATE227268T1 (de) | 2002-11-15 |
Family
ID=26309398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97920270T ATE227268T1 (de) | 1996-04-10 | 1997-04-08 | Alpha v beta 3 antagonisten |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0901373B1 (de) |
| JP (1) | JP2000508319A (de) |
| AT (1) | ATE227268T1 (de) |
| AU (1) | AU720758B2 (de) |
| CA (1) | CA2251017A1 (de) |
| DE (1) | DE69716900T2 (de) |
| ES (1) | ES2185009T3 (de) |
| WO (1) | WO1997037655A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9708265D0 (en) * | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
| DE69720771T2 (de) * | 1996-10-30 | 2004-01-29 | Merck & Co Inc | Integrin antagonist |
| US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6211191B1 (en) | 1997-12-17 | 2001-04-03 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6066648A (en) | 1997-12-17 | 2000-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| WO1999052872A1 (en) | 1998-04-09 | 1999-10-21 | Meiji Seika Kaisha, Ltd. | AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS |
| AU4385399A (en) * | 1998-06-29 | 2000-01-17 | Biochem Pharma Inc. | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer |
| PL345574A1 (en) * | 1998-07-06 | 2001-12-17 | Scripps Research Inst | Angiogenesis inhibitors |
| JP2002522540A (ja) * | 1998-08-13 | 2002-07-23 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| CZ20011395A3 (cs) | 1998-10-22 | 2001-08-15 | F. Hoffmann-La Roche Ag | Deriváty thiazolu |
| SE9803773D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Pharma Prod | Compounds |
| MXPA01010232A (es) | 1999-04-13 | 2002-03-27 | Basf Ag | Ligandos de receptores de integrina. |
| IL146378A0 (en) | 1999-06-02 | 2002-07-25 | Merck & Co Inc | Alpha v integrin receptor antagonists |
| AU5379900A (en) | 1999-06-07 | 2000-12-28 | Shire Biochem Inc. | Thiophene integrin inhibitors |
| BR0012683A (pt) | 1999-07-21 | 2002-04-16 | American Home Prod | Antagonistas bicìclicos seletivos para a integrina alfavbeta3 |
| AU6316900A (en) | 1999-08-05 | 2001-03-05 | Meiji Seika Kaisha Ltd. | Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alphavbeta3antagonism |
| DE10006139A1 (de) * | 2000-02-11 | 2001-08-16 | Merck Patent Gmbh | Indol-3-yl-Derivate |
| EP1381384B1 (de) | 2001-04-24 | 2011-05-25 | Merck Patent GmbH | KOMBINATIONSTHERAPIE MIT ANTIANGIOGENEN MITTELN UND TNFalpha |
| NZ535169A (en) | 2002-03-12 | 2006-03-31 | Wyeth Corp | Process for making chiral 1,4-disubstituted piperazines |
| EP1483255B1 (de) | 2002-03-12 | 2009-08-12 | Wyeth | Verfahren zur herstellung von chiralen n-aryl piperazinen |
| US7091349B2 (en) | 2002-03-12 | 2006-08-15 | Wyeth | Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution |
| US7361773B2 (en) | 2002-03-12 | 2008-04-22 | Wyeth | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
| DK1483243T3 (da) | 2002-03-12 | 2007-08-06 | Wyeth Corp | Fremstilling af N1-(2'-pyridyl)-1,2-propandiaminsulfaminsyre og dens anvendelse i syntesen af biologisk aktive piperaziner |
| WO2005054188A1 (en) * | 2003-12-02 | 2005-06-16 | Ucb, S.A. | Imidazole derivatives, processes for preparing them and their uses |
| ES2521679T3 (es) | 2006-01-18 | 2014-11-13 | Merck Patent Gmbh | Terapia específica usando ligandos de integrinas para el tratamiento del cáncer |
| WO2008087025A2 (en) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Specific therapy and medicament using integrin ligands for treating cancer |
| NZ597339A (en) | 2009-05-25 | 2013-10-25 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
| ES2605939T3 (es) * | 2012-01-27 | 2017-03-17 | F. Hoffmann-La Roche Ag | Conjugados de antagonistas de la integrina para una administración dirigida a células que expresan alfa-V-beta-3 |
| KR20160147007A (ko) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체 |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4505911A (en) * | 1983-10-13 | 1985-03-19 | Mead Johnson & Company | Isoindole diuretic derivatives, compositions and use |
| US5272158A (en) * | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| DE4414880A1 (de) * | 1994-04-28 | 1995-11-02 | Basf Ag | Schwefelverbindungen |
| US5646000A (en) * | 1994-09-29 | 1997-07-08 | Merck & Co., Inc. | Compounds and methods for identifying activated platelets |
| TR199801255T2 (xx) * | 1995-12-29 | 1998-10-21 | Smithkline Beecham Corporation | Vitronektin resept�r antagonistleri. |
| BR9612381A (pt) * | 1995-12-29 | 1999-07-13 | Smithkline Beecham Corp | Antagonistas receptores vitronectina |
| AU724216B2 (en) * | 1997-04-07 | 2000-09-14 | Merck & Co., Inc. | A method of treating cancer |
-
1997
- 1997-04-08 EP EP97920270A patent/EP0901373B1/de not_active Expired - Lifetime
- 1997-04-08 DE DE69716900T patent/DE69716900T2/de not_active Expired - Fee Related
- 1997-04-08 JP JP9536469A patent/JP2000508319A/ja active Pending
- 1997-04-08 AU AU24501/97A patent/AU720758B2/en not_active Ceased
- 1997-04-08 CA CA002251017A patent/CA2251017A1/en not_active Abandoned
- 1997-04-08 WO PCT/US1997/005890 patent/WO1997037655A1/en not_active Ceased
- 1997-04-08 AT AT97920270T patent/ATE227268T1/de not_active IP Right Cessation
- 1997-04-08 ES ES97920270T patent/ES2185009T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0901373A1 (de) | 1999-03-17 |
| DE69716900T2 (de) | 2003-07-03 |
| AU720758B2 (en) | 2000-06-08 |
| JP2000508319A (ja) | 2000-07-04 |
| CA2251017A1 (en) | 1997-10-16 |
| EP0901373B1 (de) | 2002-11-06 |
| DE69716900D1 (de) | 2002-12-12 |
| AU2450197A (en) | 1997-10-29 |
| EP0901373A4 (de) | 1999-07-07 |
| ES2185009T3 (es) | 2003-04-16 |
| WO1997037655A1 (en) | 1997-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE227268T1 (de) | Alpha v beta 3 antagonisten | |
| ES2194223T3 (es) | Antagonistas de la integrina. | |
| ATE298338T1 (de) | Integrin-rezeptor-antagonisten | |
| DE69829996D1 (de) | Integrin-rezeptor-antagonisten | |
| DE69830806D1 (de) | Integrinrezeptor antagonisten | |
| CA2277273A1 (en) | Integrin antagonists | |
| IL146378A0 (en) | Alpha v integrin receptor antagonists | |
| AU7793501A (en) | Alpha v integrin receptor antagonists | |
| WO2002090325A3 (en) | Benzazepinone alpha v integrin receptor antagonists | |
| YU38200A (sh) | Antagonisti integrinskog receptora | |
| YU38300A (sh) | Antagonisti integrinskog receptora |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |